Navigation Links
Nutra Pharmaceutical's U.S. distributor, XenaCare Holdings Announces National Print Advertising Campaign for Cobroxin, a Treatment for Moderate to Severe (Stage 2) Pain

Nutra Pharmaceutical's U.S. distributor, XenaCare Holdings announced that its national print advertising campaign for Cobroxin, the first clinically proven, over-the-counter treatment for moderate to severe (stage 2) chronic pain, is scheduled to begin in November and will run in Arthritis Today, Prevention, Health, Star, Woman's World, Soap Opera, and Self Magazines.

(Vocus) September 4, 2009 -- Cobroxin, which was developed by Nutra Pharma Corporation (OTCBB: NPHC), is the first opiate and acetaminophen-free pain reliever available as an over-the-counter formulation that is clinically proven to treat moderate to severe (Stage 2) chronic pain. In August, Nutra Pharma granted XenaCare Holdings the exclusive license for marketing and distributing Cobroxin throughout the United States.

XenaCare Holdings, Inc. (OTCBB: XCHO), a company specializing in the marketing and retail distribution of consumer healthcare products, has announced today that it will begin its national print advertising campaign for Cobroxin in November. The campaign, which is budgeted at approximately $550,000, is scheduled to run through December and will appear in Arthritis Today, Prevention, Health, Star, Woman's World, Soap Opera, and Self magazines.

“This advertising campaign represents the first of several national campaigns we plan to roll out as we introduce Cobroxin through national retailers in the coming months,” explained Frank Rizzo, President of XenaCare Holdings, Inc. “In addition to print advertising, we are also finalizing online marketing campaigns and television commercials,” he concluded.


Read the full story at

Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved  

Related biology technology :

1. Neptune Technologies Reports Fiscal 2009 Results - Record revenue and profitability growth in nutraceutical business
2. Industry Expert Reveals Cutting Edge Biotechnology Science for Nutraceutical and Functional Food Applications
3. EnWave Successfully Commercializes nutraREV(TM) Food Dehydration Technology
4. NutraCea Appoints New Chief Financial Officer
5. Synutra Announces Postponement of Proposed Offering
6. Eniva VIBE(R) Nutraceutical Tested at Linus Pauling Micronutrient Research Institute and Found to Possess DNA Protective Properties
7. Celtic Pharma Holdings Announces Investment in Novacta Biosystems Limited
8. Lixte Biotechnology Holdings Lead Compound, LB-1.2, Enhances the Effectiveness of Standard Cancer Chemotherapy in Animal Models
9. Excalibur International Marine (49% Owned by EFT BioTech Holdings) Completes Inaugural Passenger Crossing of Taiwan Strait
10. Zimmer Holdings Announces Live Audio Webcast and Conference Call of Second Quarter 2009 Results
11. EFT BioTech Holdings, Inc.s Sea Vessel Completes Inaugural Passenger Voyage Across the Taiwan Strait
Post Your Comments:
Related Image:
Nutra Pharmaceutical's U.S. distributor, XenaCare Holdings Announces National Print Advertising Campaign for Cobroxin, a Treatment for Moderate to Severe (Stage 2) Pain
(Date:6/23/2016)... /PRNewswire/ - FACIT has announced the creation of ... company, Propellon Therapeutics Inc. ("Propellon" or "the Company"), ... portfolio of first-in-class WDR5 inhibitors for the treatment ... represent an exciting class of therapies, possessing the ... cancer patients. Substantial advances have been achieved with ...
(Date:6/23/2016)... 2016  The Biodesign Challenge (BDC), a university competition ... harness living systems and biotechnology, announced its winning teams ... New York City . The ... projects at MoMA,s Celeste Bartos Theater during the daylong ... senior curator of architecture and design, and Suzanne ...
(Date:6/23/2016)... 23, 2016 Apellis Pharmaceuticals, Inc. today ... trials of its complement C3 inhibitor, APL-2. The ... ascending dose studies designed to assess the safety, ... injection in healthy adult volunteers. Forty ... a single dose (ranging from 45 to 1,440mg) ...
(Date:6/23/2016)... WI (PRWEB) , ... June 23, 2016 , ... ... focused on quality, regulatory and technical consulting, provides a free webinar ... presented on July 13, 2016 at 12pm CT at no charge. , Incomplete ...
Breaking Biology Technology:
(Date:4/19/2016)... -- The new GEZE SecuLogic access control ... system solution for all door components. It can be ... interface with integration authorization management system, and thus fulfills ... dimensions of the access control and the optimum integration ... considerable freedom of design with regard to the doors. ...
(Date:4/13/2016)... , April 13, 2016  IMPOWER physicians supporting Medicaid ... setting a new clinical standard in telehealth thanks to ... leveraging the higi platform, IMPOWER patients can routinely track ... and body mass index, and, when they opt in, ... convenient visit to a local retail location at no ...
(Date:3/23/2016)... Massachusetts , March 23, 2016 /PRNewswire/ ... im Interesse erhöhter Sicherheit Gesichts- und Stimmerkennung ... Xura, Inc. (NASDAQ: MESG ), ... bekannt, dass das Unternehmen mit SpeechPro zusammenarbeitet, ... aus der Finanzdienstleistungsbranche, wird die Möglichkeit angeboten, ...
Breaking Biology News(10 mins):